Cancer testis antigen and immunotherapy

被引：45
|
作者：
Krishnadas, Deepa Kolaseri [1 ]
Bai, Fanqi [1 ]
Lucas, Kenneth G. [1 ]
机构：
[1] Univ Louisville, Dept Pediat, Div Hematol Oncol, Louisville, KY 40292 USA
来源：
IMMUNOTARGETS AND THERAPY | 2013年 / 2卷
关键词：
cancer testis antigens; immunotherapy; vaccine;
D O I：
10.2147/ITT.S35570
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in several different tumors. This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antigen family A, 3 (MAGE-A3), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in various malignancies, and presents our current understanding of CT antigen based immunotherapy.
引用
收藏
页码：11 / 19
页数：9
相关论文
共 50 条
  • [21] Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy
    Mirandola, Leonardo
    Pedretti, Elisa
    Figueroa, Jose A.
    Chiaramonte, Raffaella
    Colombo, Michela
    Chapman, Caroline
    Grizzi, Fabio
    Patrinicola, Federica
    Kast, W. Martin
    Nguyen, Diane D.
    Rahman, Rakhshanda Layeequr
    Daver, Naval
    Ruvolo, Peter
    Post, Sean M.
    Bresalier, Robert S.
    Chiriva-Internati, Maurizio
    ONCOTARGET, 2017, 8 (43) : 74378 - 74390
  • [22] Lymphoblastoid cell lines as potential vaccines for the immunotherapy of cancer testis antigen-expressing tumors
    Kaddu-Mulindwa, D.
    Neumann, F.
    Kubuschok, B.
    Pfreundschuh, M.
    ONKOLOGIE, 2010, 33 : 276 - 277
  • [23] Identification of a novel cancer-testis antigen as a target for the immunotherapy of acute myeloid leukaemia (AML)
    Hardwick, N. R.
    Ingram, W.
    Farzaneh, F.
    Mufti, G. J.
    Guinn, B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 19 - 20
  • [24] PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy
    C D O Cooper
    A P Liggins
    K Ait-Tahar
    G Roncador
    A H Banham
    K Pulford
    Leukemia, 2006, 20 : 2172 - 2174
  • [25] PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy
    Cooper, C. D. O.
    Liggins, A. P.
    Ait-Tahar, K.
    Roncador, G.
    Banham, A. H.
    Pulford, K.
    LEUKEMIA, 2006, 20 (12) : 2172 - 2174
  • [26] Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
    Afsheen Raza
    Maysaloun Merhi
    Varghese Philipose Inchakalody
    Roopesh Krishnankutty
    Allan Relecom
    Shahab Uddin
    Said Dermime
    Journal of Translational Medicine, 18
  • [27] Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
    Raza, Afsheen
    Merhi, Maysaloun
    Inchakalody, Varghese Philipose
    Krishnankutty, Roopesh
    Relecom, Allan
    Uddin, Shahab
    Dermime, Said
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [28] Cancer-testis antigens: Targets for cancer immunotherapy
    Chen, YT
    Old, LJ
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (01): : 16 - 17
  • [29] Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
    Yousef, Sara
    Heise, Johanna
    Lajmi, Nesrine
    Bartels, Katrin
    Kroeger, Nicolaus
    Luetkens, Tim
    Atanackovic, Djordje
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [30] Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis
    Yokoe, Takeshi
    Tanaka, Fumiaki
    Mimori, Koshi
    Inoue, Hiroshi
    Ohmachi, Takahiro
    Kusunoki, Masato
    Mori, Masaki
    CANCER RESEARCH, 2008, 68 (04) : 1074 - 1082
12345